Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
drugs
5
×
life sciences
national blog main
boston blog main
boston top stories
clinical trials
fda
national top stories
new york blog main
new york top stories
patisiran
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
akcea therapeutics
alnylam pharmaceuticals
boston
inotersen
onpattro
rna interference
san francisco
tafamidis
accelerator
acute hepatic porphyrias
airbnb
akin akinc
amazon web services (aws)
aminolevulinic acid
anylam pharmaceuticals
artificial intelligence (a.i.)
athelas
atomwise
barry greene
benchling
biotech
biotechnology
boston university
cancer
cannabidiol
What
ago
5
×
fda
alnylam
drug
medicine
approved
battle
patients
pharmaceuticals
rare
rna
sets
weeks
admits
akcea
amyloidosis
approval
approve
attr
available
awaits
big
biological
biotechs
cannabis
classes
combinator
companies
crossed
data
debilitating
decades
decision
derivative
discovered
disease
dug
epilepsy
fingers
form
Language
unset
Current search:
drugs
×
ago
×
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
5 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug